                         SEQUENCE LISTING

<110>  Dizal (Jiangsu) Pharmaceutical Co., Ltd.
 
<120>  NOVEL ANTI-FGFR2B ANTIBODIES

<130>  070542-8007WO03

<160>  10    

<170>  PatentIn version 3.5

<210>  1
<211>  5
<212>  PRT
<213>  Mus musculus


<220>
<221>  HCDR1
<222>  (1)..(5)

<400>  1

Ser Gly Tyr Tyr Trp 
1               5   


<210>  2
<211>  11
<212>  PRT
<213>  Mus musculus


<220>
<221>  LCDR1
<222>  (1)..(11)

<400>  2

Lys Ala Ser Gln Ser Val Ser Asn Asp Val Ala 
1               5                   10      


<210>  3
<211>  16
<212>  PRT
<213>  Mus musculus


<220>
<221>  HCDR2
<222>  (1)..(16)

<400>  3

Tyr Ile Thr Tyr Asp Gly Ser Asn Asn Tyr Asn Pro Ser Leu Lys Asn 
1               5                   10                  15      


<210>  4
<211>  7
<212>  PRT
<213>  Mus musculus


<220>
<221>  LCDR2
<222>  (1)..(7)

<400>  4

Tyr Ala Ser Asn Arg Tyr Thr 
1               5           


<210>  5
<211>  11
<212>  PRT
<213>  Mus musculus


<220>
<221>  HCDR2
<222>  (1)..(11)

<400>  5

Val Tyr Tyr Tyr Gly Ser Gly Asn Phe Asp Val 
1               5                   10      


<210>  6
<211>  9
<212>  PRT
<213>  Mus musculus


<220>
<221>  LCDR3
<222>  (1)..(9)

<400>  6

His Gln Asp His Thr Ser Pro Phe Thr 
1               5                   


<210>  7
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Ab26/26c ANTIBODIES HEAVY CHAIN VARIABLE REGION AMINO ACID 
       SEQUENCE

<400>  7

Asp Val His Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 
1               5                   10                  15      


Ser Leu Ser Leu Thr Cys Ser Val Thr Gly Tyr Ser Ile Thr Ser Gly 
            20                  25                  30          


Tyr Tyr Trp Asn Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp 
        35                  40                  45              


Met Gly Tyr Ile Thr Tyr Asp Gly Ser Asn Asn Tyr Asn Pro Ser Leu 
    50                  55                  60                  


Lys Asn Arg Leu Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Phe 
65                  70                  75                  80  


Leu Gln Leu Ser Ser Leu Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys 
                85                  90                  95      


Ala Arg Val Tyr Tyr Tyr Gly Ser Gly Asn Phe Asp Val Trp Gly Thr 
            100                 105                 110         


Gly Thr Thr Val Thr Val Ser Ser 
        115                 120 


<210>  8
<211>  360
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Ab26/26c ANTIBODIES HEAVY CHAIN VARIABLE REGION CODING SEQUENCE

<400>  8
gatgtacacc ttcaggagtc aggacctggc ctcgtgaaac cttctcagtc tctgtctctc       60

acctgctctg tcactggcta ctccatcacc agtggttatt actggaactg gatccggcag      120

tttccaggga acaaactgga atggatgggc tacataacct acgatggtag caataactac      180

aacccatctc tcaaaaatcg actctccatc actcgtgaca catctaagaa ccagtttttc      240

ctgcaattga gttctttgac aactgaggac acagccacat acttctgtgc aagagtttat      300

tactacggta gtgggaactt cgatgtctgg ggcacaggga ccacggtcac cgtctcctca      360


<210>  9
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Ab26/26c ANTIBODIES LIGHT CHAIN VARIABLE REGION AMINO ACID 
       SEQUENCE

<400>  9

Ser Ile Val Met Thr Gln Thr Pro Lys Ile Leu Leu Val Ser Ala Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Ser Val Ser Asn Asp 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Tyr Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly 
    50                  55                  60                  


Ser Gly Tyr Gly Thr Asp Phe Thr Phe Thr Ile Ser Thr Val Gln Ala 
65                  70                  75                  80  


Glu Asp Leu Ala Val Tyr Phe Cys His Gln Asp His Thr Ser Pro Phe 
                85                  90                  95      


Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  10
<211>  321
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Ab26/26c ANTIBODIES LIGHT CHAIN VARIABLE REGION CODING SEQUENCE

<400>  10
agtattgtga tgacccagac tcccaaaatc ctgcttgtat cagcaggaga cagggttacc       60

ataacctgca aggccagtca gagtgtgagt aatgatgtag cttggtacca acagaagcca      120

gggcagtctc ctaaactgct gatatattat gcatctaatc gctacactgg agtccctgat      180

cgcttcactg gcagtggata tgggacggat ttcaccttca ccatcagcac tgtgcaggct      240

gaagacctgg cagtttattt ctgtcaccag gatcatacct ctccattcac gttcggctcg      300

gggacaaagt tggaaataaa a                                                321


